Drug Profile
Research programme: miniaturised sustained release therapeutics - EyePoint Pharmaceuticals
Alternative Names: TBD; Tethadur™ - EyePoint PharmaceuticalsLatest Information Update: 25 Nov 2021
Price :
$50
*
At a glance
- Originator pSivida
- Developer EyePoint Pharmaceuticals
- Class Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Age-related macular degeneration; Glaucoma; Retinitis pigmentosa
Most Recent Events
- 28 Mar 2018 pSivida is now called EyePoint Pharmaceuticals
- 04 Nov 2017 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in USA (Ophthalmic, Controlled release)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Glaucoma in USA (Ophthalmic, Controlled release)